A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
Article
Raez, LE, Santos, ES, Webb, RT et al. (2013). A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 72(5), 1103-1110. 10.1007/s00280-013-2301-z
Raez, LE, Santos, ES, Webb, RT et al. (2013). A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)
. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 72(5), 1103-1110. 10.1007/s00280-013-2301-z